IL-33 down-regulates CLDN1 expression through the ERK/STAT3 pathway in keratinocytes

Journal of Dermatological Science

Volumn 90, Issue 3, 2018, Pages 313-322

  Ryu, Woo In ^a   Lee, Hana ^a   Bae, Hyun Cheol ^a   Jeon, Jiehyun ^a   Ryu, Hwa Jung ^a   Kim, Jaehyung ^a   Kim, Ji Hyun ^a   Son, Ji Won ^a   Kim, JaeYoung ^a   Imai, Yasutomo ^b   Yamanishi, Kiyofumi ^b   Jeong, Sang Hoon ^a   Son, Sang Wook ^a  

^a Korea University College of Medicine   (South Korea)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Claudin 1; Extracellular signal regulated kinase; IL 33; Keratinocytes; Signal transducer and activator of transcription 3

Indexed keywords

CLAUDIN 1; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; INTERLEUKIN 33; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; CLDN1 PROTEIN, HUMAN; CLDN1 PROTEIN, MOUSE; IL33 PROTEIN, HUMAN; IL33 PROTEIN, MOUSE; STAT3 PROTEIN, HUMAN; STAT3 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOPIC DERMATITIS; CONTROLLED STUDY; DOWN REGULATION; ELECTRIC RESISTANCE; ENZYME PHOSPHORYLATION; FLUX ASSAY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; KERATINOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSEPITHELIAL ELECTRIC RESISTANCE; UPREGULATION; WESTERN BLOTTING; ANIMAL; CYTOLOGY; DOG; EPIDERMIS; MAPK SIGNALING; MDCK CELL LINE; METABOLISM; PATHOLOGY; TIGHT JUNCTION; TRANSGENIC MOUSE;

ANIMALS; CLAUDIN-1; DERMATITIS, ATOPIC; DOGS; DOWN-REGULATION; EPIDERMIS; HUMANS; INTERLEUKIN-33; KERATINOCYTES; MADIN DARBY CANINE KIDNEY CELLS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; STAT3 TRANSCRIPTION FACTOR; TIGHT JUNCTIONS;

EID: 85043350896     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2018.02.017     Document Type: Article

References (46)

1. Madison, K.C., Barrier function of the skin:la raison d'etre of the epidermis. J. Invest. Dermatol. 121:2 (2003), 231–241.
2. Capaldo, C.T., Nusrat, A., Cytokine regulation of tight junctions. Biochimica et Biophysica Acta (BBA)-Biomembranes 1788:4 (2009), 864–871.
3. Förster, C., Tight junctions and the modulation of barrier function in disease. Histochem. Cell Biol. 130:1 (2008), 55–70.
4. Mineta, K., Yamamoto, Y., Yamazaki, Y., Tanaka, H., Tada, Y., Saito, K., Tamura, A., Igarashi, M., Endo, T., Takeuchi, K., Predicted expansion of the claudin multigene family. FEBS Lett. 85:4 (2011), 606–612.
5. Tsukita, S., Furuse, M., Itoh, M., Multifunctional strands in tight junctions. Nat. Rev. Mol. Cell Biol. 2:4 (2001), 285–293.
6. A, De Benedetto, Rafaels, N.M., L.Y, McGirt, Ivanov, A.I., Georas, S.N., Cheadle, C., Berger, A.E., Zhang, K., Vidyasagar, S., Tight junction defects in patients with atopic dermatitis. J. Allergy Clin. Immunol. 127:3 (2011), 773–786 (e7).
7. Hadj-Rabia, S., Baala, L., Vabres, P., Hamel-Teillac, D., Jacquemin, E., Fabre, M., Lyonnet, S., de Prost, Y., Munnich, A., Hadchouel, M., Claudin-1 gene mutations in neonatal sclerosing cholangitis associated with ichthyosis: a tight junction disease. Gastroenterology 127:5 (2004), 1386–1390.
8. Furuse, M., Hata, M., Furuse, K., Yoshida, Y., Haratake, A., Sugitani, Y., Noda, T., Kubo, A., Tsukita, S., Claudin-based tight junctions are crucial for the mammalian epidermal barrier. J. Cell Biol. 56:6 (2002), 1099–1111.
9. Sugawara, T., Iwamoto, N., Akashi, M., Kojima, T., Hisatsune, J., Sugai, M., Furuse, M., Tight junction dysfunction in the stratum granulosum leads to aberrant stratum corneum barrier function in claudin-1-deficient mice. J. Dermatol. Sci. 0:1 (2013), 12–18.
10. Hönzke, S., Wallmeyer, L., Ostrowski, A., Radbruch, M., Mundhenk, L., Schäfer-Korting, M., Hedtrich, S., Influence of Th2 cytokines on the cornified envelope, tight junction proteins, and β-defensins in filaggrin-deficient skin equivalents. J. Invest. Dermatol. 136:3 (2016), 631–639.
11. Yuki, T., Tobiishi, M., Kusaka-Kikushima, A., Ota, Y., Tokura, Y., Impaired tight junctions in atopic dermatitis skin and in a skin-equivalent model treated with interleukin-17. PLoS One, 11(9), 2016, e0161759.
12. Niehues, H., Schalkwijk, J., van Vlijmen-Willems, I.M., Rodijk-Olthuis, D., van Rossum, M.M., Wladykowski, E., Brandner, J.M., van den Bogaard, E.H., Zeeuwen, P.L., Epidermal equivalents of filaggrin null keratinocytes do not show impaired skin barrier function. J. Allergy Clin. Immunol. 139:6 (2017), 1979–1981 (e13).
13. Gruber, R., Börnchen, C., Rose, K., Daubmann, A., Volksdorf, T., Wladykowski, E., Vidal-y-Sy, S., Peters, E.M., Danso, M., Bouwstra, J.A., Diverse regulation of claudin-1 and claudin-4 in atopic dermatitis. Am. J. Pathol. 185:10 (2015), 2777–2789.
14. Watson, R., Poddar, R., Walker, J., McGuill, I., Hoare, L., Griffiths, C., O'neill, C., Altered claudin expression is a feature of chronic plaque psoriasis. J. Pathol. 212:4 (2007), 450–458.
15. Kirschner, N., Poetzl, C., von den Driesch, P., Wladykowski, E., Moll, I., Behne, M.J., Brandner, J.M., Alteration of tight junction proteins is an early event in psoriasis: putative involvement of proinflammatory cytokines. Am. J. Pathol. 75:3 (2009), 1095–1106.
16. Cevikbas, F., Steinhoff, M., IL-33: a novel danger signal system in atopic dermatitis. J. Invest. Dermatol. 132:5 (2012), 1326–1329.
17. Lloyd, C.M., IL-33 family members and asthma?bridging innate and adaptive immune responses. Curr. Opin. Immunol. 22:6 (2010), 800–806.
18. Savinko, T., Matikainen, S., Saarialho-Kere, U., Lehto, M., Wang, G., Lehtimäki, S., Karisola, P., Reunala, T., Wolff, H., Lauerma, A., IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. J. Invest. Dermatol. 132:5 (2012), 1392–1400.
19. Bulek, K., Swaidani, S., Aronica, M., Li, X., Epithelium: the interplay between innate and Th2 immunity. Immunol. Cell Biol. 88:3 (2010), 257–268.
20. Liew, F.Y., Pitman, N.I., McInnes, I.B., Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 10:2 (2010), 103–110.
21. Xu, D., Chan, W.L., Leung, B.P., Huang, F.-p., Wheeler, R., Piedrafita, D., Robinson, J.H., Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J. Exp. Med. 187:5 (1998), 787–794.
22. Tjota, J.W., Williams, T., Lu, B.S., Clay, T., Byrd, C.L., Hrusch, D.C., Decker, C.A., de Araujo, P.J., Bryce, A.I., IL-33–dependent induction of allergic lung inflammation by Fc γRIII signaling. J. Clin. Invest., 123(5), 2013, 2287.
23. Haenuki, K., Matsushita, S., Futatsugi-Yumikura, K.J., Ishii, T., Kawagoe, Y., Imoto, S., Fujieda, M., Yasuda, Y., Hisa, S., A critical role of IL-33 in experimental allergic rhinitis. J. Allergy Clin. Immunol. 130:1 (2012), 184–194 (e11).
24. Tamagawa-Mineoka, Y., Okuzawa, K., Masuda, N., Increased serum levels of interleukin 33 in patients with atopic dermatitis. J. Am. Acad. Dermatol. 70:5 (2014), 882–888.
25. Sundnes, O., Pietka, W., Loos, T., Sponheim, J., Rankin, A.L., Pflanz, S., Bertelsen, V., Sitek, J.C., Hol, J., Haraldsen, G., Epidermal expression and regulation of interleukin-33 during homeostasis and inflammation: strong species differences. J. Invest. Dermatol. 135:7 (2015), 1771–1780.
26. Imai, Y., Yasuda, K., Sakaguchi, Y., Haneda, T., Mizutani, H., Yoshimoto, T., Nakanishi, K., Yamanishi, K., Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc. Natl. Acad. Sci. 110:34 (2013), 13921–13926.
27. Akira, S., Nishio, Y., Inoue, M., Wang, X.-J., We, S., Matsusaka, T., Yoshida, K., Sudo, T., Naruto, M., Kishimoto, T., Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77:1 (1994), 63–71.
28. Fukada, T., Hibi, M., Yamanaka, Y., Takahashi-Tezuka, M., Fujitani, Y., Yamaguchi, T., Nakajima, K., Hirano, T., Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity 5:5 (1996), 449–460.
29. Yamanaka, Y., Nakajima, K., Fukada, T., Hibi, M., Hirano, T., Differentiation and growth arrest signals are generated through the cytoplasmic region of gp130 that is essential for Stat3 activation. EMBO J., 15(7), 1996, 1557.
30. AM, Siegel, K.D., Stone, G., Cruse, M.G., Lawrence, A., Olivera, Jung, J.S., Barber, A.F., Freeman, S.M., Holland, M., Diminished allergic disease in patients with STAT3 mutations reveals a role for STAT3 signaling in mast cell degranulation. J. Allergy Clin. Immunol. 132:6 (2013), 1388–1396 (e3).
31. Kim, J.H., Bae, H.C., Ko, N.Y., Lee, S.H., Jeong, S.H., Lee, H., Ryu, W.-I., Kye, Y.C., Son, S.W., Thymic stromal lymphopoietin downregulates filaggrin expression by signal transducer and activator of transcription 3 (STAT3) and extracellular signal-regulated kinase (ERK) phosphorylation in keratinocytes. J. Allergy Clin. Immunol., 136(1), 2015, 205.
32. Lee, H., Ryu, W.-I., Kim, H.J., Bae, H.C., Ryu, H.J., Shin, J.J., Song, K.-H., Kim, T.W., Son, S.W., TSLP down-regulates S100A7 and ß-defensin 2 via the JAK2/STAT3-dependent mechanism. J. Invest. Dermatol. 136:12 (2016), 2427–2435.
33. Jamaluddin, M.S., Wang, X., Wang, H., Rafael, C., Yao, Q., Chen, C., Eotaxin increases monolayer permeability of human coronary artery endothelial cells. Arterioscler. Thrombosisnd Vasc. Biol. 29:12 (2009), 2146–2152.
34. Lennon, F.E., Mirzapoiazova, T., Mambetsariev, B., Poroyko, V.A., Salgia, R., Moss, J., Singleton, P.A., The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. PLoS One, 9(3), 2014, e91577.
35. Haneda, T., Imai, Y., Uchiyama, R., Jitsukawa, O., Yamanishi, K., Activation of molecular signatures for antimicrobial and innate defense responses in skin with transglutaminase 1 deficiency. PLoS One, 11(7), 2016, e0159673.
36. Nickoloff, B.J., Naidu, Y., Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J. Am. Acad. Dermatol. 30:4 (1994), 535–546.
37. Proksch, E., Brandner, J.M., Jensen, J.M., The skin: an indispensable barrier. Exp. Dermatol. 17:12 (2008), 1063–1072.
38. Batista, D., Perez, L., Orfali, R., Zaniboni, M., Samorano, L., Pereira, N., Sotto, M., Ishizaki, A., Oliveira, L., Sato, M., Profile of skin barrier proteins (filaggrin, claudins 1 and 4) and Th1/Th2/Th17 cytokines in adults with atopic dermatitis. J. Eur. Acad. Dermatol. Venereol. 29:6 (2015), 1091–1095.
39. Yokouchi, M., Kubo, A., Kawasaki, H., Yoshida, K., Ishii, K., Furuse, M., Amagai, M., Epidermal tight junction barrier function is altered by skin inflammation, but not by filaggrin-deficient stratum corneum. J. Dermatol. Sci. 77:1 (2015), 28–36.
40. Chalubinski, M., Wojdan, K., Luczak, E., Gorzelak, P., Borowiec, M., Gajewski, A., Rudnicka, K., Chmiela, M., Broncel, M., IL-33 and IL-4 impair barrier functions of human vascular endothelium via different mechanisms. Vascul. Pharmacol. 73 (2015), 57–63.
41. Pearson, G., Robinson, F., Beers Gibson, T., Xu, B., Karandikar, M., Berman, K., Cobb, M.H., Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions 1. Endocr. Rev. 22:2 (2001), 153–183.
42. Ryu, W.I., Lee, H., Kim, J.H., Bae, H.C., Ryu, H.J., Son, S.W., IL-33 induces Egr-1-dependent TSLP expression via the MAPK pathways in human keratinocytes. Exp. Dermatol. 24:11 (2015), 857–863.
43. Ying, H., Da, L., Yu-xiu, S., Yu, X., Li-xia, L., Li-mei, X., Wei-dong, R., TLR4 mediates MAPK–STAT3 axis activation in bladder epithelial cells. Inflammation 36:5 (2013), 1064–1074.
44. Youmba, S.B., Belmonte, L., Galas, L., Boukhettala, N., Bôle-Feysot, C., Déchelotte, P., Coëffier, M., Methotrexate modulates tight junctions through NF-κB, MEK, and JNK pathways. J. Pediatr. Gastroenterol. Nutr. 54:4 (2012), 463–470.
45. Wang, Y., Zhang, J., Yi, X.-j., Fu-Shin, X.Y., Activation of ERK1/2 MAP kinase pathway induces tight junction disruption in human corneal epithelial cells. Exp. Eye Res. 78:1 (2004), 125–136.
46. Basuroy, S., Seth, A., Elias, B., Naren, A.P., Rao, R., MAPK interacts with occludin and mediates EGF-induced prevention of tight junction disruption by hydrogen peroxide. Biochem. J 93:1 (2006), 69–77.